Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 4,453.8% in April

Eliem Therapeutics, Inc. (NASDAQ:ELYM) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company’s stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.

Eliem Therapeutics Stock Performance

Shares of NASDAQ ELYM opened at $3.98 on Friday. The firm has a market cap of $110.33 million, a price-to-earnings ratio of -2.71 and a beta of 0.51. The business’s 50-day simple moving average is $3.06 and its 200-day simple moving average is $2.80. Eliem Therapeutics has a 52 week low of $2.34 and a 52 week high of $5.19.

Institutional Trading of Eliem Therapeutics

A hedge fund recently raised its stake in Eliem Therapeutics stock. BML Capital Management LLC grew its position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 0.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,193,742 shares of the company’s stock after acquiring an additional 13,742 shares during the quarter. Eliem Therapeutics accounts for about 4.0% of BML Capital Management LLC’s holdings, making the stock its 7th largest position. BML Capital Management LLC owned 7.91% of Eliem Therapeutics worth $6,011,000 at the end of the most recent reporting period. 69.76% of the stock is owned by institutional investors and hedge funds.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.